Related Experiment Videos
NS-2330 (Neurosearch)
1Department of Clinical Pharmacology, BYL Nair Hospital, Mumbai, India. Clinpharm@vsnl.net
Current Opinion in Investigational Drugs (London, England : 2000)
|January 5, 2002
Summary
NeuroSearch is developing NS-2330, a novel compound targeting neurotransmitter activity, as a potential treatment for Alzheimer's and Parkinson's diseases. Clinical trials are progressing, with Phase III studies anticipated soon.
Area of Science:
- Neuroscience
- Pharmacology
Background:
- Alzheimer's disease (AD) and Parkinson's disease (PD) are neurodegenerative disorders with limited treatment options.
- NS-2330 is a compound developed by NeuroSearch aimed at increasing dopamine, norepinephrine, and acetylcholine activity.
Purpose of the Study:
- To evaluate NS-2330 as a potential therapeutic agent for Alzheimer's disease and Parkinson's disease.
- To advance the development of NS-2330 through clinical trial phases.
Main Methods:
- NS-2330 is undergoing Phase II clinical trials for Alzheimer's disease.
- A Phase II tolerability trial in Parkinson's disease patients with dyskinesia was conducted.
- Planning for Phase III studies was initiated.
Main Results:
- NeuroSearch secured funding for continued in-house development of NS-2330.
- Phase III studies were planned for Q3 2002.
- Market entry predictions for NS-2330 were made for 2007/2008 with projected market shares.
Conclusions:
- NS-2330 shows promise as a treatment for neurodegenerative diseases like AD and PD.
- Successful funding and trial progression indicate continued development efforts.
- Further clinical evaluation is necessary to confirm efficacy and safety.